ARS Pharmaceuticals (SPRY) Invested Capital (2020 - 2026)

ARS Pharmaceuticals has disclosed Invested Capital across 7 years of filings, most recently posting $157.8 million for Q1 2026.

• Invested Capital for Q1 2026 came in at $157.8 million, down 31.07% year-over-year; the trailing twelve-month figure through Mar 2026 was $157.8 million (down 31.07% YoY), and the FY2025 annual result was $214.3 million, down 16.57% from the prior year.
• Invested Capital came in at $157.8 million for Q1 2026 at ARS Pharmaceuticals, down from $214.3 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $272.9 million in Q4 2022 to a low of -$50.2 million in Q3 2022.
• The 5-year median for Invested Capital is $223.9 million (2024), against an average of $179.5 million.
• Peak annual rise in Invested Capital reached 972.7% in 2022, while the deepest fall reached 115.1% in 2022.
• ARS Pharmaceuticals' Invested Capital stood at $272.9 million in 2022, then retreated by 15.44% to $230.8 million in 2023, then advanced by 11.28% to $256.8 million in 2024, then declined by 16.57% to $214.3 million in 2025, then dropped by 26.34% to $157.8 million in 2026.
• The last three Invested Capital figures came in at $157.8 million (Q1 2026), $214.3 million (Q4 2025), and $243.9 million (Q3 2025), per Business Quant data.